Imagabalin

Imagabalin (INN, USAN; PD-0332334) was an investigational drug that acted as a ligand for the α2δ subunit of the voltage-dependent calcium channel,[1] with some selectivity for the α2δ1 subunit over α2δ2.[2] It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer.[3][4][5][6] The drug is no longer under development.

Imagabalin
Clinical data
Other namesPD-0332334; PD-332,334
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC9H19NO2
Molar mass173.256 g·mol−1
3D model (JSmol)

See also

References
  1. Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA (July 2011). "Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology". Brain Research. 1401: 1–9. doi:10.1016/j.brainres.2011.05.025. PMC 3197737. PMID 21664606.
  2. Larry Ereshefsky (2008). "Therapies in the Pipeline for Sleep Disorders: Focus on Novel Mechanisms and Disease Models" (PDF) (Press release). p. 11. Retrieved 2012-04-22.
  3. Pfizer (2012-11-09). "A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study Of PD 0332334 And Paroxetine Evaluating The Efficacy And Safety Of PD 0332334 For The Treatment Of Generalized Anxiety Disorder". Cite journal requires |journal= (help)
  4. Pfizer (2012-11-09). "A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study Of PD 0332334 And Paroxetine Evaluating The Efficacy And Safety Of PD 0332334 For The Treatment Of Generalized Anxiety Disorder". Cite journal requires |journal= (help)
  5. Pfizer (2012-11-09). "A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder". Cite journal requires |journal= (help)
  6. Pfizer (2012-11-09). "A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder". Cite journal requires |journal= (help)


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.